申请人:AstraZeneca AB
公开号:US06346633B1
公开(公告)日:2002-02-12
The invention concerns anti-tumour agents of formula (I) wherein each of R1, R2 and R3 has the meanings defined in the specification including hydrogen, (1-4C)alkyl, (3-4)alkenyl, (3-4C)alkynyl, amino, (1-4C)alkylamino and (1-4C)alkoxy; each of R4 and R5 is (1-4C)alkyl; each of R6 and R7 is hydrogen or (1-4C)alkyl; X is oxygen; m is 1 or 2 and each R8 is as defined in the specification; each of Y1 and Y2 is halogeno, (1-4C)alkanesulphonyloxy, benzenesulphonyloxy or phenyl-(1-4C)akanesulphonyloxy; or a pharmaceutically-acceptable salt thereof; provided that at least one of R1, R2 and R3 is other than hydrogen; a process for preparation, pharmaceutical compositions containing them and their use in the production of an anti-proliferative effect.
该发明涉及式(I)的抗肿瘤剂,其中R1、R2和R3中的每一个具有规范中定义的含义,包括氢、(1-4C)烷基、(3-4)烯基、(3-4C)炔基、氨基、(1-4C)烷基氨基和(1-4C)烷氧基;R4和R5中的每一个是(1-4C)烷基;R6和R7中的每一个是氢或(1-4C)烷基;X是氧;m为1或2,每个R8如规范中定义;Y1和Y2中的每一个是卤素、(1-4C)烷磺酰氧基、苯磺酰氧基或苯基-(1-4C)烷磺酰氧基;或其药用可接受盐;前提是R1、R2和R3中至少有一个不是氢;一种制备方法,含有它们的药物组合物以及它们在抗增殖作用中的应用。